Q-omics provides the consensus-scored NEK7 profile across patient tissues and cancer cell-line models. NEK7 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NEK7 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, NEK7 protein abundance shows 25,302 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, HNSC, and LUAD as cancer lineages where NEK7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NEK7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NEK7 survival associations across molecular data types. NEK7 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NEK7 RNA expression–survival associations across cancer types. High NEK7 expression shows unfavorable associations in UVM, PAAD and BLCA, but favorable associations in KIRC, UCS and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NEK7 RNA expression.
This table summarizes NEK7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for NEK7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NEK7 shows lower tumor expression in LUAD, LUSC, THCA and KICH and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher NEK7 RNA expression in tumor versus normal tissue (log2 FC = +1.371, t-test p < 0.001).
This table shows molecular features associated with NEK7 in patient tissues and cancer cell lines. In patient samples, NEK7 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, NEK7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
